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Defects in heart development are the most common congenital abnormalities in humans, providing a strong incentive to learn more about
the underlying causes. Previous studies have implicated the metalloprotease-disintegrins ADAMs (a disintegrin and metalloprotease) 17 and
19 as well as heparin binding EGF-like growth factor (HB-EGF) and neuregulins in heart development in mice. Here, we show that mice
lacking both ADAMs 17 and 19 have exacerbated defects in heart development compared to mice lacking either ADAM, providing the first
evidence for redundant or compensatory functions of ADAMs in development. Moreover, we identified additional compensatory or
redundant roles of ADAMs 9 and 19 in morphogenesis of the mitral valve and cardiac outflow tract. Cell biological studies designed to
address the functions of these ADAMs in shedding of HB-EGF uncovered a contribution of ADAM19 to this process, but this was only
evident in the absence of the major HB-EGF sheddase, ADAM17. In addition, ADAM17 emerged as the major sheddase for neuregulins h1
and h2 in mouse embryonic fibroblasts. These results raise the possibility that ADAMs 9, 17, and 19 contribute to heart development in
humans and have implications for understanding the mechanisms underlying congenital heart disease.
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Congenital heart disease is the most common form of
birth defects in humans, afflicting about 6–17/1000 live
births, yet much remains to be learned about the underlying
causes (Basson and Seidman, 1998; Goldmuntz and
Emanuel, 1997; Hoffman and Kaplan, 2002; Lamers and
Moorman, 2002; Srivastava and Olson, 2000; Vaughan and
Basson, 2000). Identifying which molecules are critical for
normal heart development and understanding their mecha-
nism of action could therefore lead to improvements in the
diagnosis and treatment of congenital heart defects. Recent0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: blobelc@hss.edu (C.P. Blobel).studies have uncovered a critical role for two members of
family of membrane-anchored metalloproteases in cardio-
vascular morphogenesis, ADAMs (a disintegrin and metal-
loprotease) 17 and 19 (Jackson et al., 2003; Kurohara et al.,
2004; Shi et al., 2003; Zhou et al., 2004). ADAMs are also
known to have important functions in a variety of other
biological processes, including fertilization, neurogenesis,
angiogenesis, and cancer (for recent reviews, see Blobel,
2005; Seals and Courtneidge, 2003; White, 2003).
The heart abnormalities observed in mice lacking func-
tional ADAM17 are thickened and misshapen semilunar
valves (aortic and pulmonic valves) and atrioventricular
valves (Jackson et al., 2003). A lack of ADAM17 also leads
to additional developmental abnormalities in mice, including
defects in epithelial structures such as skin and intestines
(Peschon et al., 1998), as well as inmorphogenesis of the lung
(Zhao et al., 2001) and mammary gland (ZenaWerb, personal
communication). The skin, lung, mammary gland, and heart283 (2005) 459 – 471
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signaling in these tissues (Jackson et al., 2003; Peschon et al.,
1998) (Zena Werb, personal communication). The under-
lying mechanism appears to be a vital role of proteolytic
processing in activating several EGFR-ligands during devel-
opment (Jackson et al., 2003; Peschon et al., 1998; for review,
see Blobel, 2005), all of which are synthesized as membrane-
anchored precursors (reviewed in Harris et al., 2003).
Specifically, ADAM17 is thought to be critical for processing
and activation of at least three EGFR-ligands: heparin
binding EGF-like growth factor (HB-EGF) (Hinkle et al.,
2004; Jackson et al., 2003; Merlos-Suarez et al., 2001; Sahin
et al., 2004), which is important for proper morphogenesis of
the semilunar and atrioventricular valves (Iwamoto et al.,
2003; Jackson et al., 2003; Yamazaki et al., 2003); trans-
forming growth factor a (TGFa) (Peschon et al., 1998; Sahin
et al., 2004), which is needed for skin, hair follicle, and eye
development (Luetteke et al., 1993; Mann et al., 1993;
Peschon et al., 1998); and amphiregulin (AR) (Sahin et al.,
2004), which is essential for branching morphogenesis and
ductal outgrowth during mammary gland development
(Luetteke et al., 1999 and Z.Werb, personal communication).
Adam19/ mice also display thickened and misshapen
semilunar valves, resembling those in newborn Adam17/
mice (Kurohara et al., 2004; Zhou et al., 2004), which
provides a likely explanation for the death of Adam19/
mice shortly after birth. However, the mechanism under-
lying the defect in semilunar valve development in
Adam19/ mice appears to be different from that
described for Adam17/ animals, since shedding of HB-
EGF is not affected in Adam19/ embryonic fibroblasts
(mEFs) (Zhou et al., 2004), while it is abolished in
Adam17/ mEFs (Hinkle et al., 2004; Sahin et al.,
2004; Sunnarborg et al., 2002). In addition to defects in
semilunar valves, Adam19/ mice also have a ventricular
septal defect (VSD) and a thickened and misshapen tricuspid
valve, but a normal mitral valve (Kurohara et al., 2004; Zhou
et al., 2004).
Interestingly, even though two separate studies reported
very similar heart defects in independently generated
Adam19/ mouse lines, only one found evidence for a
potential role of Adam19/ in processing an isoform of
neuregulin (NRG), NRG h1, an ErbB ligand which is also
synthesized as membrane-bound precursor (see Falls, 2003
for review on NRGs). Specifically, Kurohara et al. reported
a lack of phorbol-ester-stimulated processing of this NRG
isoform when Adam19/ mouse embryonic fibroblasts
(mEFs) were grown under sparse conditions, but not under
dense conditions (Kurohara et al., 2004). Based on these
findings, Kurohara et al. proposed that decreased shedding
of NRG h1 in proliferating endocardial cushion cells during
heart development might cause the heart defect in
Adam19/ mice. However, this very attractive model
could not be corroborated in similar studies using cells from
the second Adam19/ mouse line, in which no defects in
NRG processing (NRGs h1 and h2) were found, regardlessof the cell density (Zhou et al., 2004). Despite these
discrepancies, both studies were in agreement that the major
sheddase for NRG h1 in confluent mEFs is not ADAM19,
and therefore remained to be identified. Since the heart
defects in both Adam19/ mouse lines were very similar,
it therefore appeared likely that the mechanism underlying
the role of ADAM19 in heart development involves other
substrates or mechanisms than shedding of NRG (Zhou et
al., 2004).
The studies on Adam17/ and Adam19/ mice raise
a number of questions about the role of these ADAMs in
heart development. The similarity in the heart defects in
Adam17/ and Adam19/ mice and the observation
that both proteins are expressed in the developing heart and
heart valves (Jackson et al., 2003; Zhou et al., 2004) raise
the question of whether ADAMs 17 and 19 might have
compensatory or redundant functions in heart development.
The second question concerns the identity of the NRG
sheddase(s), and specifically whether other ADAMs besides
ADAM19 might be involved in NRG shedding. A previous
study has shown that ADAM17 is required for cleaving
NRG a2c (Montero et al., 2000), raising the possibility that
it might also be involved in shedding of other isoforms of
NRG, at least in densely plated cells. A third question is
whether ADAM19 could have a function in cleaving HB-
EGF in the absence of the major HB-EGF sheddase,
ADAM17.
The essential roles of ADAMs 17 and 19 in heart
development also raise questions about the contribution of
other ADAMs that are expressed in the heart to cardiovas-
cular morphogenesis. Specifically, the expression patterns
of ADAMs 9 and 19 partially overlap in the endocardial
cushion (Weskamp et al., 2002; Zhou et al., 2004), and
those of ADAMs 15 and 19 overlap in endocardial cells
overlying the endocardial cushion (Horiuchi et al., 2003;
Zhou et al., 2004). Previous studies have shown that
ADAMs 9 and 15 are not required for normal development
and adult homeostasis, and even triple knockout mice
lacking these two ADAMs together with ADAM12 are
viable and fertile with no apparent defects in heart
development (Horiuchi et al., 2003; Kurisaki et al., 2003;
Sahin et al., 2004; Weskamp et al., 2002). Furthermore,
quadruple knockout mice lacking ADAMs 9, 12, 15, and 17
do not have a more severe phenotype than mice lacking
only ADAM17, arguing against potential compensatory or
redundant functions between these four ADAMs (Sahin et
al., 2004). However, ADAMs 9, 12, and 15 are more closely
related to ADAM19 than to ADAM17 (Blobel, 2005), thus
providing a rationale for evaluating potential heart defects in
Adam9/12/15/19/ quadruple knockout mice, as well as
in different combinations of double knockout mice lacking
ADAMs 19 and 9 or ADAMs 19 and 15.
The results of this study provide the first evidence for
potential compensatory or redundant roles among different
ADAMs. In addition, we found that ADAM19 can contribute
to HB-EGF shedding, but this is only evident in the absence
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biological experiments unambiguously identified ADAM17
as the sheddase responsible for constitutive and phorbol-
ester-stimulated shedding of NRGs h1 and h2 in mouse
embryonic fibroblasts grown under both dense and sparse
conditions.Materials and methods
Generation of Adam17/19/, Adam9/19/,
Adam15/19/, and Adam9/12/15/19/ knockout mice
Mice lacking ADAM17 or ADAM19 have been
described previously (Peschon et al., 1998; Zhou et al.,
2004). Since both Adam17/ and Adam19/ mice die
shortly after birth, we mated Adam17+/,19+/ doubly
heterozygous parents, which are healthy and fertile with no
evident pathological defect (data not shown), to generate
Adam17/19/ double knockout mice. Mice lacking
ADAMs 9, 12, 15, and 19 were generated by crossing
Adam19+/ mice with Adam9/12/15/ mice, which are
viable and fertile with no major evident pathological
phenotypes (Sahin et al., 2004). The resulting offspring
that were heterozygous for ADAMs 9, 12, 15, and 19 were
backcrossed to Adam9/12/15/ mice several times to
generate Adam9/12/15/,19+/ mice. These animals
were also viable and fertile, and did not display any
evident pathological phenotype (data not shown). Adam9/
12/15/,19+/ mice were mated to generate Adam9/12/
15/19/ embryos, which had more severe defects in heart
development than mice lacking only ADAM19 (see Results
section for details). Because ADAM12 is not highly
expressed in the endocardial cushion (data not shown),
we focused on mating Adam9/ or Adam15/ mice
with Adam19+/ animals to generate doubly heterozygous
offspring. These doubly heterozygous offspring were back-
crossed with Adam9/ or Adam15/ mice to produce
either Adam9/,19+/ or Adam15/,19+/ animals.
Timed matings were set up to generate Adam9/19/ and
Adam15/19/ embryos at E18.5 for further analysis.
Genotyping was performed by PCR using specific primers
that distinguish between the targeted and wild-type allele
for ADAMs 17 and 19, or by Southern blot as previously
described for ADAMs 9, 12, and 15 (Horiuchi et al., 2003;
Kurisaki et al., 2003; Sahin et al., 2004; Weskamp et al.,
2002; Zhou et al., 2004). All animals used in this study
were of mixed genetic background (129Sv/C57Bl/6). It is
important to note that only littermates were compared with
one another, which minimizes potential effects of the
genetic background on the outcome of the experiments.
Histopathology
Histological analysis with hematoxylin–eosin staining,
and immunostaining with anti-CD31 antibody were per-formed as described previously (Zhou et al., 2004). Images
of the sections were acquired with Axiovison software via
an Axiocam HRC camera mounted on an Axioplan2
microscope (software, camera, and microscope were from
Carl Zeiss MicroImaging, Inc.). Images were processed with
Adobe Photoshop software.
Transfection and shedding assays
cDNA constructs encoding human placental secreted
alkaline phosphatase (AP)-NRG (h1 and h2) fusion proteins
(Zhou et al., 2004) or AP-tagged EGFR-ligands [HB-EGF,
TGFa, AR, and epiregulin (EPR); Sahin et al., 2004) were
cotransfected together with full-length wild-type ADAMs or
catalytically inactive mutants in which the catalytic gluta-
mate was changed to an alanine (E>A), using lipofect-
AMINE (Invitrogen) as described previously (Sahin et al.,
2004; Zheng et al., 2002; Zhou et al., 2004). The ADAM8
expression vector was kindly provided by Dr. Jo¨rg Bartsch.
The ADAM12 expression vector was generated by inserting
the ADAM12 cDNA (Inoue et al., 1998) into a pCDNA
expression vector. All other ADAM expression vectors were
described previously (Chesneau et al., 2003; Lum et al.,
1998; Sahin et al., 2004; Weskamp et al., 1996; Zhou et al.,
2004). mEFs were prepared from E13.5 wild-type or
ADAM17-deficient embryos as described in reference
(Weskamp et al., 2002). The Adam17/ fibroblast cell
line (E2 cells), derived from E13.5 embryos, has been
described previously (Reddy et al., 2000). mEFs and the cell
lines (E2 cells and COS-7 cells) were transfected with the
indicated plasmids following previously established proto-
cols (Chesneau et al., 2003; Sahin et al., 2004; Zheng et al.,
2002). Fresh Opti-MEM (Invitrogen) medium was added
the next day after the transfection, incubated for 1 h, and
then replaced with fresh medium containing 20 ng/ml PMA
with or without 1 AM batimastat (BB94, kindly provided by
Dr. D. Becherer), which was also collected after 1 h.
Detection of AP-tagged NRGs and EGFR-ligands in the
supernatant or in the cell lysate by an ‘‘in-gel’’ renaturation
and AP-detection system or by colorimetry has been
presented previously (Sahin et al., 2004; Zheng et al.,
2002). In the present study, 40 Al of a 1:1 slurry of
Concanavalin A lectin beads in cell lysis buffer was added
to 800 Al cell supernatant to concentrate the AP-tagged
NRGs and EGFR-ligands via their N-linked carbohydrate
moieties. The supernatant was incubated with Concanavalin
A lectin beads overnight at 4-C on a rotating rod. After
removing the supernatant, bound glycoproteins were eluted
in 20 Al elution buffer [50 mM Tris–HCl (pH 8), 0.5 M a-
d-methyl mannoside) at 37-C for 2 h to preserve the activity
of the AP-module, and 5 Al of 6 gel loading buffer was
added. For the ‘‘in gel’’ AP-detection procedure, the samples
(which were not boiled or reduced) were subjected to SDS-
PAGE at <100 V, and the SDS-polyacrylamide gel was then
soaked in 2.5% Triton X-100 for 1 h to renature the AP-
domain. Then, the gel was incubated in substrate buffer
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bromo-4-chloro-3-indolyl phosphate (BCIP) in 100 mM
Tris–Hcl, pH 9.5] for 2 to 3 h, or until the bands became
visible. With respect to colorimetric detection of ectodo-
main shedding, we used the ratio of AP activity in the
supernatant and the cell lysate at the end of the incubation
period to establish levels of ectodomain shedding. Gain-of-
function experiments were normalized using the ratio from
cells cotransfected with the AP-tagged ligand and an
empty vector instead of an ADAM as a standard (=1). The
ratio reflects the shedding of a given AP-tagged ligand by
a given protease in 1 h. All experiments were repeated at
least three times with similar results.
Statistical analysis
v2 test was used to evaluate whether the distribution of
the genotypes of progeny from matings of mutant mice was
Mendelian. P values of <0.05 were considered statistically
significant. All statistical analyses were performed with
Microsoft Excel software.Results
Developmental defects in Adam17/19/ mice are more
severe than in Adam17/ or Adam19/ mice
In order to address potential compensatory or redundant
roles of ADAMs 17 and 19 during development, we mated
doubly heterozygous Adam17+/,19+/ mice to generate
Adam17/19/ double knockout offspring. These matings
produced no live offspring lacking both ADAMs (0 out of
120 newborn mice, see Table 1). In addition, only half of the
expected number of Adam17/,19+/ mice were born.
By comparison, mice lacking either ADAM17 or ADAM19
are usually born alive, even though they die in the first few
days after birth (Kurohara et al., 2004; Peschon et al., 1998;
Zhou et al., 2004). When timed matings were performed
with doubly heterozygous Adam17+/19+/ parents, theTable 1
Genotype of offspring from matings of Adam17+/,19+/ parents (%)
Adam17 Adam19 P1 E14.5 E12.5 Expected
+/+ +/+ 6.7 6.5 6.3 6.25
+/ 15.0 10.8 13.1 12.5
/ 5.8 5.4 7.1 6.25
+/ +/+ 13.3 10.7 7.7 12.5
+/ 34.2 20.4 27.4 25.0
/ 15.8 17.2 13.0 12.5
/ +/+ 4.2 8.6 4.7 6.25
+/ 5.0* 12.9 15.4 12.5
/ 0.0** 7.5a 5.3 6.25
P1, n = 120; E14.5, n = 93; E12.5, n = 163.
a 6 embryos out of 7 were dead at the time of collection.
* P = 0.013.
** P = 0.005.distribution of genotypes at embryonic days E12.5–13.5
and E14.5–15.5 was close to the expected Mendelian ratio.
At E12.5–13.5, all recovered embryos had a visible
heartbeat, whereas the majority of Adam17/19/ double
knockout embryos lacked this vital sign at E14.5–15.5.
Thus, the inactivation of both ADAMs 17 and 19 had a
significantly more severe impact on mouse development
than the inactivation of only ADAM17 or ADAM19.
Histopathological analysis revealed that six of seven
hearts of Adam17/19/ double knockout embryos at
E13.5–14.5 had a severe lack of trabeculation and an
underdeveloped myocardial wall, especially of the left
ventricle, compared to wild-type or heterozygous littermates
(Figs. 1A, B). The poorly developed ventricular wall seen in
these six of seven Adam17/19/ double knockout mice
raises the possibility that the embryonic lethality around
E13.5–14.5 in Adam17/19/ mice is caused by heart
failure, although other causes cannot be ruled out. An
evaluation of the distribution of CD31-positive endocardial
cells in heart sections from E14.5 embryos of different
genotypes did not reveal defects in Adam17/19/ mice
compared to littermate controls with at least one wild-type
allele of ADAM17 or ADAM19 (Adam17+/19/,
Adam17/19+/, Adam17+/19+/, Fig. 1B). Because
remodeling of the heart valves occurs mainly after E13.5–
14.5, we were unable to determine whether the valve
malformations that are found in newborn Adam17/ or
Adam19/ animals are exacerbated in the absence of both
ADAMs 17 and 19. It should be noted that our analysis of
newborn Adam17/ mice also uncovered a ventricular
septal defect (VSD, Fig. 2), which had not been described in
previous studies of Adam17/ mice (Jackson et al., 2003;
Shi et al., 2003).
Additional heart defects in Adam9/12/15/19/ mice
compared to Adam9/12/15/ or Adam19/ animals
To address whether functions for ADAMs 9, 12, or 15
might emerge in the absence of the related ADAM19, we
generated Adam9/12/15/,19+/ mice as described in
Materials and methods. Crosses of Adam9/12/15//19+/
mice produced only 4.6% offspring lacking all four ADAMs
(Adam9/12/15/19/ mice), and thus significantly less than
the expected Mendelian ratio of 25% quadruple knockout
mice (Table 2). Since Adam19/ mice typically survive up
to several days after birth (Kurisaki et al., 2003; Zhou et al.,
2004), and since triple knockout mice lacking ADAMs 9,
12, and 15 are viable and fertile and do not have any evident
pathological phenotype (Sahin et al., 2004), these results
suggest that one or more of ADAMs 9, 12, and 15 have
compensatory or redundant functions with ADAM19. At
E18.5, the quadruple knockout embryos were present in
numbers that are consistent with Mendelian distribution
(29.6%). However, less than one third of these had a clearly
visible heartbeat at the time of collection (8.2%, 8 out of 29
Adam9/12/15/19/ embryos).
Fig. 1. Heart defects in Adam17/19/ embryos. (A) Sections of hearts from E13.5 embryos stained with hematoxylin and eosin. A heart from an Adam17/
19/ embryo (a and b) shows less trabeculation and a thinner ventricular wall (arrowheads) compared to that of Adam17+/19/ or Adam17+/19+/+
embryos (c– f). Scale bar, 500 Am (a, c, and e); 200 Am (b, d and f). (B) Heart sections from E14.5 embryos immunostained with antibodies against CD31, a
marker for endothelial/endocardial cells. The distribution of CD31-positive endocardial cells (brown staining) in an Adam17/19/ heart (a) appears similar to
the distribution in hearts from littermates of various genotypes (b, Adam17+/19/; c, Adam17/19+/; d, Adam17+/19+/). However, trabeculation
appears decreased in the heart from an Adam17/19/ embryo compared to the hearts from littermates, and the myocardial wall is thinner, especially over the
left ventricle (arrow). Abbreviations: RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; S, ventricular septum. Scale bar, 500 Am.
Fig. 2. Heart defects in newborn Adam17/ and Adam19/ mice.
Sections of hearts from Adam17/ (a and b), Adam19/ (c and d), and
wild-type (e and f) newborn mice stained with hematoxylin and eosin. A
ventricular septal defect (VSD, pointed to by arrows) and thickened aortic
valves are present in both Adam17/ and Adam19/ hearts, but not in
a wild-type control (asterisks mark the position of the aortic valve in panels
b, d, and f). Scale bar, 1000 Am (a, c, and e); 200 Am (b, d and e).
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quadruple knockout embryos at E18.5, we observed several
abnormalities that recapitulated those seen in Adam19/
mice: a VSD and hyperplastic semilunar and tricuspid
valves. In addition, each of the four Adam9/12/15/19/
mice examined had a thickened and misshapen mitral valve,
which was never found in Adam19/ mice (Fig. 3A).
Thus, valvulogenesis in Adam9/12/15/19/ mice
appeared more severely disrupted than in Adam19/
mice or in Adam9/12/15/ animals. Furthermore, all fourTable 2
Genotype of offspring from matings of Adam9,12,15/,19+/ parents
(%)
Adam9,12,15 Adam19 P1 E18.5 Expected
/ +/+ 30.9 23.5 25
+/ 64.5 46.9 50
/ 4.6* 29.6a 25
P1, n = 194; E18.5, n = 98.
a 21 embryos out of 29 were dead at the time of collection.
* P < 0.0001.
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also had a dual outlet right ventricle (DORV), in which both
the aorta and pulmonic artery emanate from the right
ventricle (Fig. 3B). This is indicative of a more severe
malrotation/malalignment defect during heart development
than what had been observed in Adam19/ mice, which
never had a DORV, although the aorta overrides the VSD in
several Adam19/ mice.
In order to determine whether lack of ADAMs 9, or 15 in
addition to ADAM19 is primarily responsible for the mitral
valve defect and the DORV in Adam9/12/15/19/ mice,
we generated double knockout mice lacking ADAMs 9 and
19, or ADAMs 15 and 19. It should be noted that mice
lacking ADAMs 19 and 12 were not generated because the
expression of ADAM12 in the developing endocardial
cushion is very low, and there is no significant overlap
with the expression of ADAM19 (data not shown). On the
other hand, ADAM9 is expressed in the endocardial cushion
(Weskamp et al., 2002), whereas ADAM15 is highly
expressed in the endocardium, including that overlying the
endocardial cushion (Horiuchi et al., 2003). Thus, the
expression patterns of ADAMs 9 and 15 overlap at least
partially with the expression of ADAM19 in the developing
endocardial cushion and overlying endocardium (Zhou et
al., 2004). Histological analysis revealed that the heart of
each of the three Adam9/19/ embryos examined at
E18.5 had enlarged mitral valves, similar to those seen in
Adam9/12/15/19/ mice, while both Adam15/19/
embryos examined at E18.5 had normal mitral valves
(Fig. 3A). Furthermore, hearts from all three Adam9/19/
animals examined also displayed a DORV (Fig. 3B). Thus,
ADAM9 has a role in mitral valve development and in
proper rotation of the outflow tract which is only uncovered
in the absence of ADAM19.
Evaluation of the contribution of ADAMs 17 and 19 to
processing of HB-EGF and other EGFR-ligands
Previous studies have shown that the processing of HB-
EGF by ADAM17 is critical for proper morphogenesis of the
heart valves (Iwamoto et al., 2003; Jackson et al., 2003;
Yamazaki et al., 2003). On the other hand, no evidence for a
major role of ADAM19 in HB-EGF cleavage was seen in
cells lacking ADAM19 (loss-of-function experiments) or in
COS-7 cells in which ADAM19 was overexpressed (gain-
of-function experiments) (Sahin et al., 2004; Zhou et al.,
2004). However, these earlier experiments did not address
the possibility that a contribution of ADAM19 to processing
HB-EGF might become apparent in cells that do not have the
major HB-EGF sheddase, ADAM17. As described previ-
ously (Zhou et al., 2004), coexpression of ADAM19 and
HB-EGF in COS-7 cells did not lead to a significant increase
in the constitutive or PMA-stimulated shedding of HB-EGF
compared to controls in which the catalytically inactive
ADAM19 (ADAM19E>A) was coexpressed (Fig. 4a).
However, when similar experiments were performed in E2cells, an immortalized cell line derived from Adam17/
mice (Reddy et al., 2000), overexpressed ADAM19 clearly
increased constitutive HB-EGF shedding compared to over-
expressed ADAM19E>A. This unanticipated result promp-
ted us to test whether ADAM19 might be able to cleave
other EGFR-ligands that are known substrates for ADAM17
in E2 cells, namely, AR, EPR, and TGFa (Peschon et al.,
1998; Sahin et al., 2004; Sunnarborg et al., 2002). As shown
Fig. 3. Defects in valve development and alignment of the outflow tract in the hearts of various Adam/ embryos. (A) Histological analysis of tricuspid and
mitral valves. Section of a normal wild-type tricuspid (a) and mitral valve (b) at E18.5 shows thin and properly remodeled valve leaflets (pointed by arrows).
Sections of the tricuspid and mitral valves in Adam9/12/15/ hearts at E18.5 (c and d) are indistinguishable from sections of wild-type valves (a and b).
Adam19/ embryos (e and f) have a thickened and misshapen tricuspid valve (e), whereas the mitral valve (f) appears normal (see also Sahin et al., 2004;
Zhou et al., 2004). In Adam9/12/15/19/ embryos, both the tricuspid valve (g) and the mitral valve (h) are thickened and misshapen. The tricuspid valves
from Adam9/19 (i) or Adam15/19/ (k) embryos resemble those of Adam19/ (e) or Adam9/12/15/19/ embryos (g), while a thickened and misshapen
mitral valve is only observed in hearts from Adam9/19/ embryos (j), but not from Adam15/19/ embryos (l). Scale bar, 100 Am. (B) Morphological
analysis of the alignment of the aorta and pulmonic artery in hearts from embryos lacking different combinations of ADAMs. In a heart from a wild-type
embryo, the pulmonic artery emanates from the right ventricle (a; blue arrowhead). A separate section shows the aorta originating from the left ventricle (b; red
arrowhead). This normal arrangement of the cardiac outflow tracts is also seen in Adam9/12/15/ embryos (c and d) and in some Adam19/ embryos
(e and f), although the aorta can also override the VSD in Adam19/ hearts (Kurohara et al., 2004; Zhou et al., 2004) (note that the VSD is not visible on the
sections in panels e and f, which were chosen to show the position of the outflow tracts). In Adam9/12/15/19/ hearts, both aorta and pulmonic artery arise
from the right ventricle, resulting in a double-outlet right ventricle (DORV, two examples shown in panels g– j). A similar malrotation/malalignment defect of
the great vessels is seen in a heart from an Adam9/19/ embryo (k and l) but not from an Adam15/19/ embryo (m and n). R, right ventricle; L, left
ventricle; scale bar, 1000 Am.
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471 465
Fig. 4. Evaluation of the ability of ADAM19 to shed EGFR-ligands in cells lacking ADAM17. (a and b) Alkaline-phosphatase (AP)-tagged EGFR-ligands
(heparin-binding EGF-like growth factor, HB-EGF; amphiregulin, AR; transforming growth factor a, TGFa; and epiregulin, EPR) were cotransfected either
with empty vector (), or with expression vector for ADAM17 (A17), ADAM19 (A19), or a catalytically inactive ADAM19 mutant (A19EA), in COS-7 cells
(a) or in ADAM17-deficient E2 cells (b). The alkaline phosphatase activity in the cell lysate (corresponding to membrane-anchored ligands) and culture
supernatant (corresponding to the released ligands) was determined as described in Materials and methods, and used to calculate the ratio between the AP-
activity in the medium and cell lysate. Black column, constitutive shedding; white column, phorbol-ester-stimulated shedding (PMA). The data are expressed as
the average of at least three independent experiments, each performed in duplicate. No significant difference in PMA-stimulated shedding of HB-EGF from
COS-7 cells expressing ADAM19 or the ADAM19E>A control or empty vector was observed (a). However, coexpression of ADAM19 with HB-EGF in
Adam17/ E2 cells increased HB-EGF shedding compared to control cells coexpressing ADAM19E>A or the empty vector (b). Shedding of AR was also
increased in E2 cells expressing ADAM19 compared to controls expressing ADAM19E>A. PMA did not significantly stimulate shedding of HB-EGF or AR
by ADAM19 (c). In-gel detection of AP-tagged ligands in the cell lysates and culture supernatant of Adam17/ E2 cells cotransfected with AP-tagged AR or
HB-EGF and ADAM19 or the inactive ADAM19E>A mutant. Release of AR and HB-EGF from E2 cells expressing ADAM19 was increased compared to
controls expressing ADAM19E>A ( P value for HB-EGF: 2.8  107; for AR: 8  1012). The supernatant of cells transfected with an empty pcDNA3
expression vector as control did not have detectable AP activity in the in-gel assay or in the colorimetric detection assay (data not shown).
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471466in Figs. 4b and c, overexpression of ADAM19 also increased
constitutive shedding of AR, but not of TGFa or EPR. The
increased shedding of HB-EGF and AR in E2 cells was not
further enhanced by addition of the phorbol ester PMA,
which is consistent with previous studies in which over-
expression of ADAM19 increased constitutive, but not
stimulated shedding of TRANCE/OPGL and TNFa (Ches-neau et al., 2003; Zheng et al., 2004). These results further
corroborate that the activity of ADAM19 in cell-based
assays is not upregulated by PMA. Thus, shedding experi-
ments in Adam17/ E2 cells revealed that ADAM19 is
capable of promoting the constitutive shedding of HB-EGF
and AR in the absence of the major sheddase for these
molecules, ADAM17. This raises the possibility that
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471 467ADAM19, which is highly expressed in the developing
endocardial cushion, and whose expression overlaps with
that of HB-EGF in the endocardial cells overlying the
cushion, might contribute to HB-EGF and AR release in
Adam17/ mice.
ADAM17, but not ADAM19, participates in the processing
of NRGs b1 and b2
Two previous studies addressing the role of ADAM19 in
shedding of NRGs (Kurohara et al., 2004; Zhou et al., 2004)
produced conflicting results (see Introduction). Specifically,
the study by Kurohara et al. found a defect in phorbol-ester-
stimulated shedding of NRG h1 in Adam19/ mEFs
grown under sparse conditions, but not dense conditions,
whereas the study of Zhou et al. did not find any evidence
for a role of ADAM19 in cleaving NRGs h1 or h2 in
sparsely or densely grown mEFs. Because we have found
that ADAM19-dependent shedding of TRANCE/OPGL and
TNFa is not stimulated by phorbol esters (Chesneau et al.,
2003; Zheng et al., 2004), whereas many ADAM17-
dependent shedding events can be enhanced by phorbol
esters, we tested the hypothesis that ADAM17 might be
responsible for shedding NRGs h1 and h2. For this purpose,
we evaluated shedding of these two NRG isoforms in mEFs
that were grown under sparse and confluent conditions, and
in immortalized E2 cells lacking ADAM17. Alkaline
phophatase (AP)-tagged NRG h1 or h2 were transfected
into mEFs from wild-type (WT) or Adam17/ mice
grown at low density (105 cells per well of six-well plate) or
high density (3  105 per well of a six-well plate). The
amount of AP-tagged NRG released into the culture
supernatant was measured in a photometric assay for AP
activity as described in Materials and methods. This showed
that both PMA-stimulated (white columns) and constitutive
ectodomain shedding (black columns) of NRGs h1 and h2
were strongly reduced in Adam17/ mEFs compared to
WT mEFs, irrespective of cell density (Fig. 5a). In COS-7
cells (Fig. 5b, left panel), shedding of both NRGs h1 and h2
was increased following addition of PMA, and decreased in
the presence of the hydroxamate-type metalloproteinase
inhibitor batimastat (BB94). In ADAM17-deficient E2 cells
(Fig. 5b, right panel), the PMA-stimulated component of the
shedding of NRBs h1 and h2 was abrogated. Addition of
BB94 further decreased the small amount of constitutive
shedding of both NRGs h1 and h2 in E2 cells.
In order to address which ADAMs besides ADAM17
might be able to cleave NRGs h1 and h2 in ‘‘gain-of-
function’’ experiments, we overexpressed ADAMs 8, 9, 10,
12, 15, or 19 together with these two NRG isoforms in
Adam17/ E2 cells. We reasoned that the activity of any
other potential NRGs h1 and h2 sheddase, including
ADAM19, should be more readily apparent in the absence
of the major sheddase, ADAM17. As a positive control, we
confirmed that overexpression of ADAM17 rescued con-
stitutive and PMA-stimulated shedding of both NRGs h1and h2 in E2 cells (Fig. 5c). However, overexpression of the
other ADAMs had no detectable effect on constitutive or
stimulated shedding of these two NRG isoforms (Fig. 5c).
The expression of each ADAM was confirmed by Western
blot analysis (data not shown), and a positive control for the
catalytic activity of ADAMs 8, 9, 10, 12, and 19 was
performed separately (data not shown; for an example of
positive controls for ADAMs 10 and 19, see Zheng et al.,
2004). In addition, we performed an ‘‘in-gel’’ assay to
visualize the AP-tagged NRGs in the supernatant and cell
lysates taken from E2 cells cotransfected with either
ADAM17 or ADAM19 (Fig. 5d). Whereas cotransfection
of ADAM17 clearly increased the amount of NRGs h1 and
h2 released into the supernatant compared to cells express-
ing ADAM17E>A, cotransfection of ADAM19 did not
result in a detectable increase in shedding of NRG h1 or h2
compared to controls expressing ADAM19E>A. The
expression of the AP-tagged NRGs in the cell lysate was
comparable, except in the case of NRG h2 cells coexpress-
ing wild-type ADAM17. Because there is increased release
of soluble NRG h2 from these cells, this is most likely due
to increased processing of cell-associated NRG h2 by
ADAM17. Taken together, these results suggest that
ADAM17 has a major role in the PMA-stimulated and
constitutive processing of NRGs h1 and h2, while no
evidence for a role of ADAM19 in processing of either of
these two NRGs was obtained (Figs. 5c and d).Discussion
This study provides the first evidence for potential
compensatory or redundant functions of members of the
ADAM protein family in development, and specifically, in
cardiovascular morphogenesis. Adam17/19/ double
knockout mice exhibit significantly more severe develop-
mental heart defects than Adam17/ or Adam19/
single knockouts, which provides a likely explanation for
their earlier embryonic lethality at E13.5–14.5. Further-
more, our results suggest that ADAMs 9 and 19 have
compensatory or redundant roles in development of the
mitral valve and in the proper rotation of the aorta and
pulmonic artery. Finally, this study explores the contribution
of these and other ADAMs to the shedding of membrane-
anchored growth factors with known functions in heart
development, HB-EGF and NRGs h1 and h2.
With respect to the mechanism underlying the functions
of ADAMs 17 and 19 in heart development, we found that
ADAM19 could shed HB-EGF in E2 cells which lack the
major HB-EGF sheddase, ADAM17. This raises the
possibility that there might be a further decrease in HB-
EGF shedding in Adam17/19/ double knockout mice in
the endocardial cushion during heart development compared
to Adam17/ mice. However, this result cannot explain
the earlier embryonic lethality of Adam17/19/ double
knockout mice compared to animals lacking only ADAM17
Fig. 5. Role of ADAMs 8, 9, 10, 12, 15, 17, and 19 in ectodomain cleavage of NRGs h1 and h2. (a) AP-tagged NRG h1 or h2 were transfected in mouse
embryonic fibroblasts (mEFs) from wild-type (WT) or Adam17/ mice (A17/) plated at low density (105 cells per well of a six-well plate) or high density
(3  105 cells per well of a six-well plate). Release of AP-tagged NRG h1 or h2 into the supernatant was determined as described in Materials and methods.
Both PMA-stimulated (white columns) and constitutive ectodomain shedding (black columns) of NRGs h1 and h2 were strongly reduced in Adam17/
mEFs compared to WT mEFs, irrespective of cell density ( P values for constitutive shedding: NRG h1, high density, 6.3  106; low density, 1.6  106;
NRG h2, high density, 3.4  106; low density, 2  104). (b) Shedding of both NRGs h1 and h2 in COS-7 cells (left panel) or Adam17/ E2 cells (right
panel) in the presence or absence of PMA or the hydroxamate-type metalloprotease inhibitor batimastat (BB94). Black column, constitutive shedding; white
column, PMA-stimulated shedding; gray column, PMA + BB94. (c) Coexpression of wild-type ADAMs (ADAMs 8, 9, 10, 12, 15, 17, and 19) or inactive
mutants for ADAMs 17 and 19 (17EA and 19EA) or empty vector with NRG h1 or h2 in Adam17/ E2 cells. The defects in PMA-stimulated and
constitutive shedding of NRG h1 and h2 in E2 cells (see also panels a and b) were rescued by ADAM17, but not by any of the other ADAMs tested here
(P values for NRG h1, ADAM17 vs. ADAM17E>A, 3  104; ADAM19 vs. ADAM19E>A, 0.58; NRG h2, ADAM17 vs. ADAM17E>A, 1.5  103,
ADAM19 vs. ADAM19E>A, 0.183). (d) In-gel assay of AP-tagged NRG h1 or h2 in the supernatant or cell lysates of Adam17/ E2 cells cotransfected
with either ADAM17 or ADAM19. No AP expression was seen in control cells transfected with an empty pcDNA3 expression vector in the in-gel assay or
the colorimetric assay (data not shown).
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471468or ADAM19, since Hb-egf/ mice survive until birth with
valve defects that strongly resemble those seen in
Adam17/ mice (Jackson et al., 2003). Nevertheless, the
ability of ADAM19 to process HB-EGF in the absence of
ADAM17 raises an interesting question about how the
substrate specificity of ADAMs is determined. Since over-
expressing ADAM19 in COS-7 cells, which possess normalendogenous ADAM17, does not significantly increase HB-
EGF shedding, even under conditions where it strongly
increases shedding of TRANCE/OPGL (Zhou et al., 2004),
one possibility is that ADAM17 somehow prevents or
reduces processing of HB-EGF by ADAM19 in COS-7
cells. Alternatively, ADAM17 might be a much more
efficient HB-EGF sheddase than ADAM19 in COS-7 cells,
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471 469in which case it could effectively compete with ADAM19
for HB-EGF processing. Another possibility is that
ADAM17 could perhaps process HB-EGF at an earlier
stage in the secretory pathway than ADAM19, thus ‘‘pre-
empting’’ cleavage by ADAM19. Further studies will be
necessary to follow up on this observation.
In one of two previous studies of Adam19/ mice,
ADAM19 was implicated in NRG h1 shedding (Kurohara
et al., 2004; Shirakabe et al., 2001). Based on this study, it
would be attractive to hypothesize that the more severe
phenotype of Adam17/19/ mice could be explained by
a contribution of both ADAMs 17 and 19 to shedding of
one or more isoforms of NRG. In this scenario, loss of
both ADAMs would more strongly affect the NRG-ErbB
signaling axis, which is known to be critical for early
heart development (Falls, 2003; Kramer et al., 1996;
Meyer and Birchmeier, 1995). However, as noted pre-
viously, the defect in stimulated NRG h1 shedding in
mEFs isolated from Adam19/ mice was only seen
under certain circumstances, namely, in sparsely plated
proliferating cells, but not in densely plated cells
(Kurohara et al., 2004). In addition, this result could not
be corroborated in a second study of Adam19/ mice
(Zhou et al., 2004). Here, we found clear evidence for a
major role of ADAM17, but not ADAM19, in stimulated
and constitutive shedding of NRGs h1 and h2, regardless
of whether the shedding experiments were performed in
sparsely or densely plated cells. Moreover, overexpression
of ADAM19 or other ADAMs in Adam17/ cells failed
to provide evidence for a role of any ADAMs except
ADAM17 in processing NRGs h1 and h2. Taken together,
these results argue against compensatory or redundant
functions of ADAMs 17 and 19 in shedding of NRGs h1
and h2. Although it cannot be ruled out that ADAM19
might contribute to shedding of NRGs h1 and h2 in other
cells besides the ones tested here, these results offer an
additional incentive to consider other potential substrates
or molecular mechanisms that could underlie the role of
ADAM19 in heart development.
In light of the critical role of NRGs, especially the
Type1 NRGs, in early heart development (Falls, 2003;
Kramer et al., 1996; Meyer and Birchmeier, 1995), it will
be interesting to explore how ADAM17-dependent shed-
ding affects the function of these and other NRGs. A
number of different splice variants of NRGs have been
described, including several that give rise to distinct
juxtamembrane ‘‘stalk’’ domains, which in turn contain
candidate cleavage sites for ectodomain sheddases such as
ADAMs (reviewed in Falls, 2003). In addition to the
identification of ADAM17 as the major sheddase of NRG
h1 and h2 in mEFs in this study, ADAM17 has also
been implicated in the shedding of NRG a2c (Montero et
al., 2000). These findings raise questions about why
Adam17/ mice do not resemble Nrg/ mice with
respect to their heart defects, whereas Adam17/ mice
closely resemble mice lacking the EGFR or several of itsligands (see Introduction). One possible explanation is
that other yet to be identified enzymes besides ADAM17
participate in shedding of different NRG isoforms during
early heart development. Another possibility is that
membrane-anchored NRG might be able to activate the
main NRG receptors, ErbB2/ErbB3, in a juxtacrine
manner during heart development, i.e., even when they
are not shed (see Blobel, 2005 for a more detailed
discussion of the potential role of shedding in juxtacrine
signaling via the EGFR versus via ErbB2/ErbB3). Further
studies will be necessary to gain a better understanding of
the role of ectodomain shedding in regulating the function
of NRGs. These will include the identification of
sheddase(s) for other NRG splice variants, evaluation of
how ectodomain shedding of NRG affects its ability to
activate ErbB2/ErbB3 and other ErbB heterodimers
during juxtacrine signaling, and establishing the respec-
tive contribution of juxtacrine and paracrine NRG signal-
ing to early heart development.
Since the analysis of Adam17/19/ double knockout
mice uncovered the first evidence for compensatory or
redundant functions of ADAMs in development, we
evaluated whether functions for ADAMs 9, 12, or 15
might emerge in a background of Adam19/ mice. We
found that Adam9/12/15/19/ quadruple knockout mice
die earlier in development than Adam19/ mice or
Adam9/12/15/ triple knockout mice, which are viable
and fertile with no evident spontaneous pathological defects
(Sahin et al., 2004). The earlier embryonic lethality in
Adam9/12/15/19/ mice is presumably caused by a
combination of a thickened and misshapen mitral valve
and a malrotation/malalignment defect of the outflow tract,
as evidenced by a double outlet right ventricle (DORV).
Both of these defects were never found in Adam19/ or
Adam9/12/15/ mice. Analysis of Adam9/19/ and
Adam15/19/ double knockout mice clearly showed that
the lack of ADAM9 in addition to ADAM19 is responsible
for the mitral valve thickening as well as the DORV. This is
consistent with the partially overlapping expression patterns
of ADAMs 9 and 19 in the endocardial cushion at E13.5
(Weskamp et al., 2002; Zhou et al., 2004). Thus, ADAMs 9
and 19 apparently have compensatory or redundant
functions in the portions of the endocardial cushion that
give rise to the mitral valve as well as to the outflow tract.
Since we found no indication for a role of ADAM9 in
shedding of NRGs h1 and h2 or HB-EGF (Sahin et al.,
2004; Weskamp et al., 2002 and current study), the
mechanism underlying the roles of ADAMs 9 and 19 in
mitral valve development remains to be determined. In
addition to potential contributions of ADAMs to proteol-
ysis or ectodomain shedding of other proteins, including
other EGFR-ligands, it is also possible that ADAMs are
critical for cell–cell or cell–matrix interactions (for review,
see White, 2003) or intracellular signaling via their
cytoplasmic domains during heart development (Blobel,
2005; Seals and Courtneidge, 2003).
K. Horiuchi et al. / Developmental Biology 283 (2005) 459–471470In summary, we present the first evidence for compensa-
tory or redundant roles of ADAMs in heart development,
which further establishes ADAMs as important factors in
this process. In addition, the finding that ADAM17 has a
major role in shedding NRGs h1 and h2 in cell-based
assays coupled with the lack of evidence for a role of
ADAM19 in shedding these two ErbB ligands provides an
incentive to continue searching for other substrates of
ADAM19 that might explain why heart valve development
is affected in Adam19/ mice. Moreover, it will be
interesting to examine the role of ADAM17 in processing
and activation of NRGs h1 and h2 and potentially also other
NRG isoforms during development. Taken together, this
study provides new insights into the role of ADAMs and
EGFR/ErbB ligands in heart development, which in turn has
implications for congenital heart disease, the most common
form of birth defects in humans.Acknowledgments
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